长城基金谭小兵：仍然看好创新药行情

Group 1 - The domestic economy showed strong resilience in Q2, and the "anti-involution" policies continue to be implemented, leading to a steady rebound in A-shares in July [1] - In August, uncertainties from overseas tariffs and rising expectations for a Federal Reserve rate cut may impact the market, while domestic policies are expected to support the stabilization of the capital market [1] - The A-share mid-year reports are entering a concentrated disclosure period, increasing the importance of performance trading [1] Group 2 - Changcheng Fund's manager, Tan Xiaobing, believes that multiple factors will influence the market in August, including unclear US-China trade tensions and the important earnings window [1] - Tan Xiaobing is optimistic about sectors such as non-bank financials, military industry, and new consumption that has been consolidating for a while [1] - The innovative drug sector is also viewed positively, although due to significant gains in July and a lack of catalysts in August, this sector may experience fluctuations until key meetings and medical insurance negotiations in September [1]